Clinical factor‐based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix

Documenti analoghi

• Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
  di: Li Chao, et al.
  Pubblicazione: (2024)
• Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024
  di: Mateus Trinconi Cunha, et al.
  Pubblicazione: (2025)
• Poor oral health and the risk of esophageal squamous cell carcinoma in Malawi
  di: Bongani Kaimila, et al.
  Pubblicazione: (2024)
• Antiapoptotic PON2 expression and its clinical implications in locally advanced oral squamous cell carcinoma
  di: Mehta Vedant Kamal, et al.
  Pubblicazione: (2024)
• Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis
  di: Yao Zhang, et al.
  Pubblicazione: (2024)